Type 1 diabetes is a lifelong autoimmune disease in which the pancreas loses its ability to produce insulin, leading to the accumulation of sugar in the bloodstream. High blood sugar is known as hyperglycemia, and it can even prove fatal if not treated. It is estimated that about 2.1 million Americans have type 1 diabetes. Insulin therapies marketed by Lilly, Novo Nordisk; and Sanofi, to name a few; Sanofi's immune therapy Tzield; CellTrans' cell therapy Lantidra; and AstraZeneca's adjunctive treatment Symlin are some of the FDA-approved treatments for type 1 diabetes. There is no cure yet for this disease.
The company we are profiling today is Lexicon Pharmaceuticals Inc. (LXRX), which is developing an adjunct therapy to insulin for type 1 diabetes in adults.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.